Nomura Asset Management
BIO icon

Nomura Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Nomura Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54K Hold
184
– – ﹤0.01% 1013
2026
Q1 		$51.3K Sell
184
-76
-29% -$21.9K ﹤0.01% 1172
2025
Q4 		$78.8K Hold
260
– – ﹤0.01% 1009
2025
Q3 		$72.9K Hold
260
– – ﹤0.01% 1015
2025
Q2 		$62.7K Sell
260
-5,290
-95% -$1.25M ﹤0.01% 1044
2025
Q1 		$1.35M Hold
5,550
– – ﹤0.01% 740
2024
Q4 		$1.82M Hold
5,550
– – 0.01% 739
2024
Q3 		$1.86M Sell
5,550
-182
-3% -$57.8K 0.01% 740
2024
Q2 		$1.57M Buy
5,732
+99
+2% +$28.8K 0.01% 745
2024
Q1 		$1.95M Sell
5,633
-124
-2% -$40.8K 0.01% 725
2023
Q4 		$1.86M Sell
5,757
-717
-11% -$225K 0.01% 725
2023
Q3 		$2.32M Sell
6,474
-1,196
-16% -$461K 0.01% 672
2023
Q2 		$2.91M Buy
7,670
+255
+3% +$104K 0.01% 638
2023
Q1 		$3.55M Buy
7,415
+621
+9% +$291K 0.02% 562
2022
Q4 		$2.86M Buy
6,794
+1,243
+22% +$502K 0.02% 601
2022
Q3 		$2.32M Buy
5,551
+590
+12% +$294K 0.01% 643
2022
Q2 		$2.46M Buy
4,961
+5
+0.1% +$2.6K 0.02% 652
2022
Q1 		$2.79M Buy
4,956
+372
+8% +$224K 0.02% 656
2021
Q4 		$3.46M Buy
4,584
+112
+3% +$83.8K 0.02% 609
2021
Q3 		$3.34M Buy
4,472
+381
+9% +$285K 0.02% 581
2021
Q2 		$2.64M Buy
4,091
+41
+1% +$25K 0.02% 659
2021
Q1 		$2.31M Buy
4,050
+48
+1% +$28.4K 0.01% 675
2020
Q4 		$2.33M Buy
4,002
+64
+2% +$36.4K 0.02% 652
2020
Q3 		$2.03M Buy
3,938
+6
+0.2% +$3.04K 0.02% 613
2020
Q2 		$1.77M Buy
3,932
+12
+0.3% +$5.3K 0.02% 624
2020
Q1 		$1.37M Buy
3,920
+360
+10% +$132K 0.01% 623
2019
Q4 		$1.32M Buy
+3,560
New +$1.26M 0.01% 737
2017
Q1 		– Sell
-130
Closed -$24K – 997
2016
Q4 		$24K Buy
+130
New +$22.2K ﹤0.01% 1295

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Nomura Asset Management's BIO Position: Q2 2026 in Review

Nomura Asset Management held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 184 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #1013.

Nomura Asset Management first reported a position in BIO in Q4 2016 and has held it in 28 quarters since. The position peaked at $3.55M in Q1 2023. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Nomura Asset Management held 184 shares of Bio-Rad Laboratories Class A worth $54K as of Q2 2026.
  • Nomura Asset Management left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Nomura Asset Management's portfolio in Q2 2026, its #1013 holding.
  • Nomura Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and has held it in 28 quarters since.
  • Nomura Asset Management's Bio-Rad Laboratories Class A position peaked at $3.55M in Q1 2023.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.